Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Saudi Arabia

 

UAE primary care platform doubles in size, targets Saudi

HBI catches up with Abhishek Sharma, CEO of Foundation Holdings which is putting $125m towards building a primary care platform in the UAE. It has doubled its national footprint in the last 18 months and is targeting Saudi Arabia and the whole region next.
September 25, 2019

NMC Health shares soar as investors bid for stake: but is it a serious offer?

Unnamed groups, one linked to Chinese conglomerate Fosun, have reportedly bid nearly $2bn for a 40% stake in London-listed global healthcare group NMC Health, according to a Reuters story, sending the share price soaring on the same day as its H1 2019 results. But the offer looks like it is still far below NMC Health's peak share price of August 2018, so why on earth would they sell now? We give the reaction of analysts, advisers and investors. 
August 22, 2019

Babylon valued at $2bn after $550m fundraising round

UK-based telehealth provider Babylon is now Europe's largest digital health company after new investors committed $550m in a Series C round, signalling a partnership with one of America's largest healthcare companies, Centene, is on the cards.
August 2, 2019

Bridgepoint “exploring” €2bn sale/IPO of Diaverum

As first reported by HBI, dialysis group Diaverum looks certain to be sold by Bridgepoint. Reuters now suggests that Diaverum is "exploring" and "testing the appetite" for a €2bn sale of the global dialysis group Diaverum. We go through potential buyers.
August 1, 2019

Jefferies and HSBC disagree on NMC

Investment bank Jefferies has issued another critical note of NMC Health, reducing its price target again and dissecting its goodwill and lease liability reporting. HSBC, meanwhile, still prefers it in the UAE over Mediclinic, citing demographic changes. NMC Health gives us its rebuttals to Jefferies' note.
July 10, 2019

Interview: Dimitris Moulavasilis, CEO, Diaverum 

Will international dialysis group Diaverum IPO or sell? We catch up with its new CEO, the former boss of international imaging group Affidea. Rarely have we met such an enthusiastic leader. That may be just as well. Many wonder whether Diaverum, which has been owned by private equity house Bridgepoint since 2007, can ever be sexed up enough to attract a top price. If anyone can achieve this, it is Moulavasilis. 
July 3, 2019
Older posts
Newer posts

Our Services

Company

Resources

Log in
Register
Log in
Register

Our Services

Company

Resources

Find Us